AAAAAA

   
Results: 1-8 |
Results: 8
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
Authors: Picard, V Angelini, E Maillard, A Race, E Clavel, F Chene, G Ferchal, F Molina, JM
Citation: V. Picard et al., Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine, J INFEC DIS, 184(6), 2001, pp. 781-784
Once-daily regimen may increase drug holidays - Reply
Authors: Molina, JM Ferchal, F Chene, G
Citation: Jm. Molina et al., Once-daily regimen may increase drug holidays - Reply, J INFEC DIS, 183(10), 2001, pp. 1539-1540
Astrovirus enteritis in a chronic lymphocytic leukemia patient treated with fludarabine monophosphate
Authors: Coppo, P Scieux, C Ferchal, F Clauvel, JP Lassoued, K
Citation: P. Coppo et al., Astrovirus enteritis in a chronic lymphocytic leukemia patient treated with fludarabine monophosphate, ANN HEMATOL, 79(1), 2000, pp. 43-45
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients
Authors: Molina, JM Ferchal, F Rancinan, C Raffi, F Rozenbaum, W Sereni, D Morlat, P Journot, V Decazes, JM Chene, G
Citation: Jm. Molina et al., Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients, J INFEC DIS, 182(2), 2000, pp. 599-602
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients
Authors: Molina, JM Cheuc, G Ferchal, F Journot, V Pellegrin, I Sombardier, MN Rancinan, C Cotte, L Madelaine, I Debord, T Decazes, JM
Citation: Jm. Molina et al., Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients, ANTIVIR TH, 4, 1999, pp. 71-74
Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study
Authors: Masquelier, B Descamps, D Carriere, I Ferchal, F Collin, G Denayrolles, M Ruffault, A Chanzy, B Izopet, J Buffet-Janvresse, C Schmitt, MP Race, E Fleury, HJA Aboulker, JP Yeni, P Brun-Vezinet, F
Citation: B. Masquelier et al., Zidovudine resensitization and dual HIV-1 resistance to zidovudine and lamivudine in the Delta lamivudine roll-over study, ANTIVIR TH, 4(2), 1999, pp. 69-77
Stavudine resistance: an update on susceptibility following prolonged therapy
Authors: Lin, PF Gonzalez, CJ Griffith, B Friedland, G Calvez, V Ferchal, F Schinazi, RF Shepp, DH Ashraf, AB Wainberg, MA Soriano, V Mellors, JW Colonno, RJ
Citation: Pf. Lin et al., Stavudine resistance: an update on susceptibility following prolonged therapy, ANTIVIR TH, 4(1), 1999, pp. 21-28
The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus
Authors: Molina, JM Chene, G Ferchal, F Journot, V Pellegrin, I Sombardier, MN Rancinan, C Cotte, L Madelaine, I Debord, T Decazes, JM
Citation: Jm. Molina et al., The ALBI trial: A randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus, J INFEC DIS, 180(2), 1999, pp. 351-358
Risultati: 1-8 |